SEC Form 4 reporting owner

Lillie James Woodruff

Lillie James Woodruff has filed 25 Form 4 transactions reported between January 27, 2026 and August 17, 2026, as Chief Scientific Officer of MapLight Therapeutics, Inc..

Name as filed: Lillie James Woodruff

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$2.6M
20 lines
Companies
1
with Form 4 filings
Latest transaction
Aug 17, 2026
transaction date

Roles and reported holdings

  • MPLTMapLight Therapeutics, Inc.
    Jan 27, 2026 – Aug 17, 2026

    Chief Scientific Officer

    Held directly202,380 sh as of Aug 3, 2026 · Form 4

    24 months: $2.6M sold

Transaction history

All 25 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 17, 2026MPLTChief Scientific OfficerGrant or awardCode A · direct31,395—Form 4
Aug 17, 2026MPLTChief Scientific OfficerGrant or awardCode A · direct7,730—Form 4
Aug 3, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct22,082$277K@ $12.54Form 4
Jul 17, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct2,077$79K@ $37.90Form 4
Jul 16, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct12$456@ $37.96Form 4
Jul 16, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct3,526$131K@ $37.26Form 4
Jul 16, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct5,009$183K@ $36.45Form 4
Jul 15, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct12$450@ $37.54Form 4
Jul 15, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct5,393$199K@ $36.99Form 4
Jul 15, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct2,238$81K@ $36.00Form 4
May 7, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct721$20K@ $28.28Form 4
May 6, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct16,421$478K@ $29.13Form 4
May 6, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct8,390$235K@ $28.04Form 4
May 5, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct963$28K@ $29.00Form 4
May 5, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct10,132$285K@ $28.12Form 4
May 4, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct705$21K@ $30.08Form 4
May 4, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct320$9K@ $29.56Form 4
May 4, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct5,526$157K@ $28.37Form 4
May 4, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct9,250$254K@ $27.50Form 4
Apr 16, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct2,097$58K@ $27.49Form 4
Apr 16, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct686$19K@ $27.01Form 4
Apr 15, 2026MPLTChief Scientific OfficerOpen-market saleCode S · direct1,730$46K@ $26.82Form 4
Feb 5, 2026MPLTChief Scientific OfficerGrant or awardCode A · direct31,395—Form 4
Feb 5, 2026MPLTChief Scientific OfficerGrant or awardCode A · direct7,730—Form 4
Jan 27, 2026MPLTChief Scientific OfficerShares withheld for tax or exercise priceCode F · direct45,055$810K@ $17.98Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.